HER2-Positive Breast Carcinoma — Research

HER2-Positive Breast Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-14	4,992	`("HER2-Positive Breast Carcinoma"[tiab] OR "HER2 Positive Breast Cancer"[tiab] OR "HER2 Overexpressing Breast Carcinoma"[tiab] OR "HER2 Overexpressing Subtype of Breast Carcinoma"[tiab] OR "ERBB2 Overexpressing Subtype of Breast Carcinoma"[tiab])`	2026-09-14	pubmed
Last 5 years	2021-01-01 → 2026-12-31	2,511	`("HER2-Positive Breast Carcinoma"[tiab] OR "HER2 Positive Breast Cancer"[tiab] OR "HER2 Overexpressing Breast Carcinoma"[tiab] OR "HER2 Overexpressing Subtype of Breast Carcinoma"[tiab] OR "ERBB2 Overexpressing Subtype of Breast Carcinoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-14	pubmed
Last 12 months	2025-09-14 → 2026-09-14	568	`("HER2-Positive Breast Carcinoma"[tiab] OR "HER2 Positive Breast Cancer"[tiab] OR "HER2 Overexpressing Breast Carcinoma"[tiab] OR "HER2 Overexpressing Subtype of Breast Carcinoma"[tiab] OR "ERBB2 Overexpressing Subtype of Breast Carcinoma"[tiab]) AND (2025/09/14:2026/09/14[dp])`	2026-09-14	pubmed

Data updated 16 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (39)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 39 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet Oncol · 2016 · PMID 26874901 · validated civic_curation pubmed
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
· N Engl J Med · 2005 · PMID 16236737 · validated civic_curation pubmed
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
· N Engl J Med · 2001 · PMID 11248153 · validated civic_curation pubmed
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.